pubmed: "j dermatolog treat"...
J Dermatolog Treat. 2022 Apr 8:1-12. doi: 10.1080/09546634.2022.2062281. Online ahead of print.ABSTRACTAs aberrant IL-17 signaling plays a critical role in the pathogenesis of psoriasis, biologic agents targeting this pathway have become an important weapon against this disease. Some biologic agents such as IL-17 inhibitors (secukinumab and ixekizumab)...
J Dermatolog Treat. 2022 Apr 6:1-7. doi: 10.1080/09546634.2022.2062278. Online ahead of print.NO ABSTRACTPMID:35385363 | DOI:10.1080/09546634.2022.2062278
J Dermatolog Treat. 2022 Apr 6:1-19. doi: 10.1080/09546634.2022.2062280. Online ahead of print.ABSTRACTBACKGROUND: Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion...
J Dermatolog Treat. 2022 Apr 6:1-28. doi: 10.1080/09546634.2022.2060924. Online ahead of print.ABSTRACTObjectives Evaluate relationships between changes in dermatologic assessments and quality of life (QoL) measures; quantify dermatologic symptom severity impacts on QoL in patients with psoriatic arthritis (PsA) treated with tofacitinib.Methods Data...
J Dermatolog Treat. 2022 Apr 4:1-6. doi: 10.1080/09546634.2022.2062277. Online ahead of print.ABSTRACTIsotretinoin treatment can be challenging for patients given the multiple steps required by the iPLEDGE program. Using a structured qualitative interview, this study evaluated patients' experiences and satisfaction with teledermatology to complete the...
J Dermatolog Treat. 2022 Apr 8:1. doi: 10.1080/09546634.2022.2062283. Online ahead of print.NO ABSTRACTPMID:35373694 | DOI:10.1080/09546634.2022.2062283
Costruisci il tuo feed di notizie
Pronto a fare un tentativo?
Inizia una prova di 14 giorni, nessuna carta di credito richiesta.